GMED Stock Analysis: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$81.46
2.67 (3.39%)
▲
5d:
+4.1%
30d:
+1.67%
90d:
-10.82%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GMED shows positive signals but monitor for confirmation. Market pricing in 4.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GMED shows positive signals but monitor for confirmation. Market pricing in 4.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$127.42
Based on 6.3% avg growth
INTRINSIC VALUE TODAY
$79.12
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $81.46, which is considered extended relative to its 30-day fair value range of $76.09 to $81.44. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.8) compared to its historical average (18.3). Remarkably, the market is currently pricing in an annual earnings decline of 4.8% over the next few years. This pessimistic expectation contrasts with the company's recent 66.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GMED is in a strong downtrend. The price is approaching resistance at $81.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: GMED has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (28th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $103.92 (+27.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GMED is in a strong downtrend. The price is approaching resistance at $81.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: GMED has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (28th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $103.92 (+27.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$76.09 -
$81.44
Company Quality Score
51/100
(HOLD)
Options IV Signal
28th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
73.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 28th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- BULLISH: Trading 27.6% below Wall St target ($103.92)
Trading Range Analysis
30-Day Trading Range
$76.09 -
$81.44
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$5.88
(7.2%)
Support & Resistance Levels
Support Level
$74.51
Resistance Level
$81.79
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.83
Wall Street Target
$103.92
(+27.6%)
Revenue Growth (YoY)
27.0%
Earnings Growth (YoY)
66.7%
Profit Margin
18.9%
Valuation Discount vs History
-4.8% cheaper
PE vs Historical
15.8 vs 18.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-4.8%
(market-implied from PE analysis)
1-Year Target
$77.55
(-5%)
2-Year Target
$73.83
(-9%)
3-Year Target
$70.28
(-14%)
3-Yr Target (if PE normalizes)
(PE: 16→18)
$81.24
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 8.5%)
$136.38
(+67%)
Base:
(SPY PE: 15.8, Growth: 8.5%)
$104.16
(+28%)
Bear:
(PE: 13.5, Growth: 8.5%)
$88.54
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 18.41 | Current EPS (TTM): $4.28
Bull Case
$104.19
(+28%)
Analyst growth 20.2%, PE expands to 20.3
Base Case
$94.72
(+16%)
Market implied 20.2%, PE stable at 18.4
Bear Case
$53.58
(-34%)
Severe decline -20.0%, PE contracts to 15.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.8 to 18.3
Stabilization Target:
$94.16
(+15.6%)
PE Expansion Potential:
+15.6%
Share & Embed Analysis
Last updated: August 04, 2026 2:07 AM ET
Data refreshes hourly during market hours. Next update: 3:07 AM
Data refreshes hourly during market hours. Next update: 3:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
1
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Kelly Huller
SELL
20000 shares
2026-02-25
Kelly Huller
SELL
10000 shares
2026-02-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$64 | 55 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$93 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$384 | 51 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$118 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 52 HOLD |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
